Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
Interpace Biosciences, Inc.Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30,...
13 methods worldwide expansion improves company options
It is been a tough financial time throughout most industries these earlier decades for the duration of COVID, but if you have the wherewithal to...